Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Celltrion Sees Sales Dip In Q3
South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.
Towa Raises Japanese Expectations Amid Uncertain Business Climate
Towa has issued a minor upward revision to its full-year guidance after its domestic business delivered higher than expected sales and profit growth during H1, but uncertainty in the Japanese generics market and concerns over the firm’s overseas units have led some analysts to raise questions.
JB Chemicals Sustains Revenue Momentum For Another Quarter
India’s JB Chemicals has seen double-digit growth in its international business and “market beating growth” in its domestic business. The company continues to perform well on the back of new launches, despite COVID-related headwinds.
Nichi-Iko Offers Heartfelt Apology As It Forecasts Huge Annual Loss
Nichi-Iko’s first-half financial results made for unhappy reading again as the company’s bottom line was battered by longstanding quality problems, leading the firm to announce huge projected losses for its current financial year ending in March 2022.
Sawai Maintains Strong Domestic Performance, Continues To Flounder In US
Sawai’s Q2 results mirrored those of Q1, with a strong performance in Japan but a weak one in the US. The firm is continuing to focus on establishing new production facilities in both territories.
Wockhardt’s UK Business Continues To Grow
Wockhardt’s UK segment continues to grow as the company records a 66% increase for the second quarter ending 30 September 2021. The company’s India market and Irish market performed well, while its emerging markets and US market failed to deliver.
Rovi Remains ‘Bullish’ On Enoxaparin Biosimilar With Much Room To Grow
Spain’s Laboratorios Farmaceuticos Rovi has set out why it remains confident in its prospects for its Becat (enoxaparin) biosimilar to Sanofi’s Lovenox/Clexane while providing an update for the firm’s Doria once-a-month injectable formulation of risperidone.
Perrigo Suffers As It Waves Goodbye To Rx
Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.
US Price Erosion Dents Alembic
Challenging phase for Alembic as continued price erosion in the US hurts earnings, while a compliance re-inspection by the FDA at an injectables site results in 10 observations. Investors believe US sales may have bottomed out at current levels but can the Indian firm bounce back quickly?
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.